Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - SuperGen Inc. (NasdaqNM:SUPG)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | Msgs | Insider | Options | Reports
Location
4140 Dublin Blvd., Suite 200
Dublin, CA 94568
Phone: (925) 560-0100
Fax: (925) 327-7347
Email: investor_relations@supergen.com
Employees (last reported count): 91
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Investor Relations
 ·Employment
 ·Subsidiaries
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 71%
·Over the last 6 months:
 · one insider buy; 182.0K shares (0.8% of insider shares)
·Institutional: 24% (84% of float)
(132 institutions)
·Net Inst. Buying: 329.0K shares (+3.94%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
SuperGen Inc. is a pharmaceutical company dedicated to the acquisition, rapid development and commercialization of oncology therapies for solid tumors and hematological malignancies. The Company's cancer products include Rubitecan, Nipent, Decitabine, Avicine, Lucanthone and 4-HC, as well as Generic Anticancer Drugs. The Company is also working on the application of its technologies to the development of improved formulations of existing anticancer agents, which will be marketed as brand name pharmaceuticals. These include Extra Technology, Spartaject Drug Delivery Technology, Oral Prodrug Delivery Technology, Cremophor-Free Paclitaxel, Inhaled Cancer Drugs and Surface Safe.
More from Market Guide: Expanded Business Description

Financial Summary
SuperGen is a pharmaceutical company dedicated to the acquisition, rapid development and commercialization of oncology therapies for solid tumors and hematological malignancies. For the six months ended 6/30/01, total revenues rose 35% to $5.4 million. Net loss increased 73% to $26.7 million. Results reflect higher domestic and European sales of Nipent due to additional marketing efforts by the sales staff, offset increased costs related to clinical trials.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Pay

Joseph Rubinfeld, Ph.D., 68
Pres, CEO, Director
$1.3M
Karl Mettinger, M.D., Ph.D., 57
Sr. VP, CMO
126K
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc..
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:SUPGAs of 31-Aug-2001
Price and Volume
52-Week Low
on 22-Mar-2001
$8.00 
Recent Price$11.74 
52-Week High
on 10-Nov-2000
$23.688
Beta0.50 
Daily Volume (3-month avg)177.5K
Daily Volume (10-day avg)137.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change-43.3%
52-Week Change
relative to S&P500
-24.0%
Share-Related Items
Market Capitalization$387.0M
Shares Outstanding33.0M
Float9.60M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$4.03 
Earnings (ttm)-$1.41 
Earnings (mrq)-$0.42 
Sales (ttm)$0.26 
Cash (mrq)$2.48 
Valuation Ratios
Price/Book (mrq)2.91 
Price/EarningsN/A 
Price/Sales (ttm)45.81 
Income Statements
Sales (ttm)$8.49M
EBITDA (ttm)-$53.7M
Income available to common (ttm)-$46.5M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-29.05%
Return on Equity (ttm)-31.17%
Financial Strength
Current Ratio (mrq)9.80 
Debt/Equity (mrq)0 
Total Cash (mrq)$81.2M
Short Interest
As of 8-Aug-2001
Shares Short1.26M
Percent of Float13.1%
Shares Short
(Prior Month)
1.23M
Short Ratio10.49 
Daily Volume120.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.